INTRODUCTION
============

LlaGI is a restriction--modification (RM) enzyme isolated from *Lactococcus lactis* ssp. cremoris W10 ([@B1],[@B2]). It is encoded on the epigenetic element pEW104 and comprises the fusion of four putative protein domains ([Figure 1](#F1){ref-type="fig"}A and B): an mrr-family nuclease ([@B3],[@B4]); a Superfamily 2 (SF2) helicase ([@B1]; a γ-type adenine methyltransferase (MTase) ([@B1]); and a target recognition domain (TRD) ([@B1]). Comparing the LlaGI primary amino acid sequences to the bacterial and archaeal sequences currently listed in the REBASE database ([@B2]) identifies 69 additional single polypeptide, helicase-containing RM enzymes ([Table 1](#T1){ref-type="table"}). Of these, two distinct groupings were noted on the basis of characteristic Walker A box sequences in their helicase domains: those with a GTGKT sequence which includes LlaGI (56 members) and those with an RFGKT sequence (14 members). Studies of *Lactococcus* bacteriophage infection show that LlaGI has efficient RM activity, producing at least a thousand-fold decrease in infectivity ([@B1]). However, details of the reaction mechanism of LlaGI, or any of the related enzymes, are not known. Whilst helicase-nuclease domain fusions are also found in the ATP-dependent Type I and Type III RM enzymes ([@B5],[@B6]), and nuclease-MTase domain fusions are typical to many sub-classes of Type II RM enzymes ([@B7; @B8; @B9]), the fusion of all three elements is unique to LlaGI and related enzymes. Thus LlaGI can be considered the prototype of a new sub-type of RM enzymes. On the basis of similarities in amino acid motifs and domain organisation, Madsen and Josephsen ([@B1]) suggested that LlaGI is a variant of the Type I RM enzymes. Here, and in the accompanying papers ([@B10],[@B11]), we provide an in-depth biochemical analysis of the *in vitro* enzymatic activities of LlaGI. On the basis of this data we discuss below the relationship of LlaGI to other RM enzymes of Types I, II and III, and suggest a suitable familial classification that is consistent with both domain organisation and function. Figure 1.The LlaGI RM enzyme. (**A**) The SacI-NsiI region of pEW104 identified previously as sufficient for *in vivo* RM activity ([@B1]). The approximate locations of the putative promoter (P) and terminator (T) of the operon are indicated. (**B**) The *llagiRM* gene product is a single polypeptide, multi-domain protein ([@B1]). Protein domain boundaries were estimated using secondary structure prediction and alignment with LlaBIII (not shown). Target Recognition Domain (TRD). (**C**) Recognition sequence of LlaGI. The adenine residue that is methylated is indicated by a circle. The arrowhead defines the directionality of the site according to cleavage ([Figure 4](#F4){ref-type="fig"}) and translocation assays ([@B10]). The 'top strand' sequence (i.e. that starting with CT) is quoted throughout. Table 1.LlaGI-like sequences identified from REBASE ([@B2])GTGKT subgroup (56 sequences)    AauTCORF264PCdpORF453PLlaSKORF6P    AavORF578PCglORF3009PLmoDORFAP    AspFBORF4323PCsyMAORFGPMboAORF2049P    AviDJORF22890PDvuORF2175PMboBCGORF2043P    BfrYORF1980PEsaRM24PMboBCGTORF2038P    BheHORF15450PGthNGORF2804PMpePMORF102P    BovEORF2337PHacSORF1335PMspELB17ORFDP    BtrCIPORF1006PHpy99ORF612PMtuCTORF2082P    BtrCIPORF1021PHpyAORF668PMtuFORF12055P    BtrCIPORF1035PHpyGORF629PMxa6833447ORFDP    BtrCIPORF1053PHpyHORF652PMxa6833447ORFFP    BtrCIPORF1064PHpyPORF680PMxaDKORF1808P    BtrCIPORF1080PHpySORF3515PNeuCORF2561P    BtrCIPORF1105PHso2336ORF1665PNfaORF2220P    BtrCIPORF14PLbiPAORF5032PPdi8503ORF1520P    BtrCIPORF164PLbiPORF33PPsyTORF37P    BtrCIPORF2491PLinCORF21PRspKDORF4062P    BtrCIPORF455PLlaBIIITha33315P    BtrCIPORF541PLlaGIRFGKT subgroup (14 sequences)    BthAHORF843PLdeBBORF1654PPpeRS5ORF3P    BthVORF4013PLlaBIIPSth1066ORF1376P    DolHORF905PNspJCORF1588PSth18311ORF1376P    LacORF475PPgiCORF415PSthLMDORF13303P    Lbr367ORF22PPgiTORF1696P[^2]

MATERIALS AND METHODS
=====================

DNA
---

All oligonucleotides were supplied by MWG biotech (Germany). Plasmid pOne is pUC19 ([@B12]), and is re-named here for clarity. pZero was derived from pOne by QuikChange mutagenesis (Stratagene, La Jolla, CA) using primers 5′-CCCGGCAACAATTAATAGA[**T**]{.ul}**TGGATG**GAGGCGGATAAAGTTGC-3′ and 5′-GCAACTTTATCCGCCTC**CATCCA[A]{.ul}**TCTATTAATTGTTGCCGGG-3′ (where the LlaGI sequence is highlighted in bold and the mutated base pair underlined). The library of two-site plasmids ([Figure 3](#F3){ref-type="fig"}) was generated by directional cloning of duplex oligonucleotides into the XbaI/HindIII fragment of plasmid pOne. One strand of each duplex oligonucleotide is shown in [Figure 3](#F3){ref-type="fig"}B (white background). Where the sites are in direct repeat (where the 'top strand' sequences in [Figure 3](#F3){ref-type="fig"} are on the same DNA strand), the plasmids are named pHT for [h]{.ul}ead-to-[t]{.ul}ail. Where the sites are in indirect repeat, the plasmids are named pHH for [h]{.ul}ead-to-[h]{.ul}ead (note that these DNA have sites in both head-to-head and tail-to-tail orientation). The sequence of Site β is denoted by a numeric suffix ([@B1; @B2; @B3; @B4; @B5; @B6; @B7; @B8; @B9; @B10; @B11; @B12; @B13; @B14]), Site α being constant ([Figure 3](#F3){ref-type="fig"}B). Linear DNA substrates for the site identification experiments were produced by PCR using Pfu polymerase as directed by the manufacturer's recommendations. Sequences of the primers used are available from M.D.S. on request. Figure 2.Purification and solution stoichiometry of LlaGI. (**A**) Lanes from separate SDS polyacrylamide gels showing stages in the protein purification protocol. G.F., gel filtration. The Post G.F. lane represents 5 µg of purified RM.LlaGI. See 'Materials and Methods' section for full details. (**B**) Elution profile of 263 µg (14.7 µM) LlaGI from a 24 ml Superose 6 column. 100 µl of protein sample was eluted in TMD Buffer plus 15 mM NaCl at 0.4 ml/min. Protein was monitored using absorbance at 280 nm. The elution volumes of the thyroglobulin (669 kDa) and carbonic anhydrase (29 kDa) standards are indicated in red. Indicated in blue are the putative elution volumes of a LlaGI monomer and dimer assuming a theoretical MW of 179 kDa (calculated from the full length amino acid sequence). *(Inset)* The apparent molecular weight of LlaGI was evaluated from the elution volume using a series of standards ('Materials and Methods' section). The red line indicates a least squares linear fit. Figure 3.Cleavage of LlaGI recognition sequences. (**A**) A library of two-site DNA substrates were generated from pOne ([Figure 4](#F4){ref-type="fig"}) by cloning different LlaGI sequences (Site β -- see B). Site α was constant in each case. For three of the sequences both directly-repeated and indirectly-repeated copies of Site β were tested. Example agarose gel shown where CC is Covalently closed Circular substrate DNA, OC is Open Circle nicked intermediate and FLL is the Full Length Linear product cleaved in both strands. DNA and LlaGI were incubated for 10 min. (**B**) Sequences of sites tested with outcome for indirectly-repeated (HtH) and directly-repeated (HtT) arrangements of sites: C, dsDNA cleavage; N, nicking only; n.d., not determined. pOne sequence is highlighted in grey, cloned sequence in white, constant LlaGI sequence in yellow and degenerate positions in red (dG), green (dA), blue (dC), purple (dT). Sequence shown is the 'top strand' as defined in [Figure 1](#F1){ref-type="fig"}C.

pRSFLlaGI was generated as follows: The *llagiRM* gene was amplified from pEW104 ([@B1]) by PCR using oligonucleotides 5′-GCGTAAGTCCCATGGTGGCATTTTGGAAGG-3′ and 5′-GCGTAAGTCGGATCCTTATTCTTGAATTTCAAATTCTGGTAA-3′; The PCR product was digested with NcoI and BamHI and inserted into pETDuet-1 (Novagen, Germany) digested with NcoI and BglII; The NcoI-XhoI fragment containing the *llagiRM* gene was then inserted into pRSFDuet-1 (Novagen, Germany); The *llagiRM* gene was fully sequenced. pET28OrfX was generated as follows: The *orfx* gene was amplified from pEW104 by PCR using oligonucleotides 5′-CGAGCCCATATGATGAGTGAAAAGTTAAAG-3′ and 5′-CTAGCTCTCGAGTCATTTTACATTCCTTCC-3′; The PCR product was digested with NdeI and XhoI and inserted into pET28a (Novagen, Germany); The *his~6~-orfX* gene was fully sequenced.

To prepare DNA for biochemical assays, *E. coli* Top10 (Invitrogen, CA, USA) or XL10-Gold (Stratagene) were transformed with the required plasmid, grown in LB medium and the DNA extracted using either commercial protocols (Qiagen, Hilden, Germany) or by density gradient centrifugation in CsCl-ethidium bromide ([@B13]). For experiments requiring ^3^H-labelled DNA, transformants were grown in M9 minimal medium supplemented with 37 MBq/l \[^3^H-methyl\] thymidine. Linear DNA substrates were generated by incubating 4 nM plasmid DNA with 1 U/μl of AlwNI or 2 U/μl of NdeI in NEBuffer 2 (New England Biolabs, MA, USA). The DNA was purified by phenol/chloroform and chloroform extraction followed by ethanol precipitation. DNA concentrations were determined from UV absorbance at 260 nm, assuming that an optical density of 1 corresponds to 50 µg/ml DNA and a molecular weight of 6.6 × 10^5^ Da/kb.

Protein expression and purification
-----------------------------------

Wild type LlaGI was purified from *E. coli* BL21 (DE3) cells (Novagen, Germany) and transformed with pRSFLlaGI. Cultures were grown in 4 L of LB medium containing kanamycin (50 μg/ml) at 37°C and 250 r.p.m. until the OD~600~ reached ∼0.4. IPTG was added to 1 mM and the cultures were incubated further at 27°C for an hour (final OD~600~ of ∼1.0). Cells were harvested, re-suspended in 45 ml of Buffer A \[50 mM Tris--Cl (pH 8.0), 150 mM NaCl, 5 mM MgCl~2~, 2.5 mM EDTA, 10% (v/v) Glycerol, 3 mM DTT, 51.7 µM phenylmethylsulfonyl fluoride, and EDTA free protease inhibitor tablets according to the manufacturer's instructions (Roche, UK)\] and lysed using a cell disruptor (Constant Systems Ltd, Northants, UK). The cell extract was clarified by centrifugation at 7358*g* for 10 min followed by 106 255*g* for 1 h 50 min. The supernatant was dialysed against Buffer B \[50 mM Tris--Cl (pH 8.0), 1 mM EDTA, 50 mM NaCl, 1 mM DTT\], 0.45 µm filtered and loaded onto two 20 ml HiPrep Heparin 16/10 FF columns (GE Healthcare UK Ltd) connected in series and equilibrated in Buffer B. Bound proteins were eluted with a linear gradient of NaCl in Buffer B (0.05--1.0 M, 400 ml). LlaGI was eluted at ∼0.40 M NaCl. Fractions containing LlaGI were pooled and, concentrated and equilibrated into Buffer B using 50 kDa cut-off centrifugal filter units (Millipore, MA, USA). The resulting sample was loaded onto an 8 ml Mono Q 10/10 column (GE Healthcare) pre-equilibrated with Buffer B. Bound proteins were eluted with a linear gradient of NaCl in Buffer B (0.05--1.0 M, 160 ml). LlaGI eluted at ∼0.38 M NaCl. Fractions containing LlaGI were pooled and concentrated as above. The resulting sample was further purified over a HiLoad 16/60 Superdex 200 pg column (GE Healthcare) pre-equilibrated in Buffer B containing 400 mM NaCl. Fractions containing LlaGI were pooled and concentrated as above, supplemented with glycerol to 50% (v/v) and stored at −20°C. The protein concentration was determined by the Bradford dye-binding procedure (Bio-Rad Protein Assay, Bio-Rad, Hemel Hempstead, UK) using bovine serum albumin (BSA) as standard. Similar concentrations (within experimental error) were determined by UV absorption at 280 nm using an extinction coefficient derived from the aromatic amino acid composition of the predicted amino acid sequences. The production and purification of the LlaGI nuclease mutant DA078 is described in the accompanying paper ([@B11]).

His~6~-tagged OrfX was purified from *E. coli* Tuner (DE3) cells (Novagen) transformed with pET28OrfX. Cultures were grown in 1 L LB medium containing 50 μg/ml kanamycin at 37°C and 250 r.p.m. until the OD~600~ reached ∼0.4. IPTG was added to 25 μM and the cultures were incubated for a further 4 h at 37°C (final OD~600~ of ∼4.5). Cells were harvested, re-suspended in 45 ml of Buffer C \[50 mM Tris--Cl (pH 8.0), 200 mM NaCl, 10 mM Imidazole, 11.1 mg/ml lysozyme\], incubated on ice for 10 min, and then lysed by cell disruption (as above). The cell extract was clarified by centrifugation at 7358*g* for 10 min followed by 106 255*g* for 37 min. The supernatant was 0.45 µm filtered, loaded onto a 5 ml HiTrap Chelating column that had been charged with NiSO~4~ (GE Healthcare), and washed in Buffer C. Bound proteins were eluted with a linear gradient of Imidazole in Buffer C (0.01--0.5 M, 50 ml). Fractions containing OrfX were pooled, and diluted 10-fold with Buffer B. The resulting sample was then loaded onto a 1 ml Mono Q 5/50 GL column (GE Healthcare) pre-equilibrated with Buffer B. Bound proteins were eluted with a linear gradient of NaCl in Buffer B (0.05--1.0 M, 20 ml). OrfX was eluted at ∼0.25 M NaCl. Fractions containing OrfX were pooled and dialysed against Buffer D \[50 mM Tris--Cl (pH 8.0), 500 mM NaCl, 10 mM Imidazole\]. The sample was then added to 20 mg Protino Ni-IDA Resin (Macherey-Nagel) and incubated at 4°C for 1 h. The beads were washed three times in Buffer D to remove unbound protein. OrfX was eluted in Buffer E \[50 mM Tris--Cl (pH 8.0), 500 mM NaCl, 500 mM Imidazole\] and then dialysed into Buffer B containing 400 mM NaCl. OrfX was supplemented with glycerol to 50% (v/v) and stored at −20°C. The protein concentration was determined by the Bradford dye-binding procedure using BSA as a standard.

EcoAI and EcoR124I methyltransferases (denoted by the prefix M) and HsdRs (denoted by the prefix R) were purified and characterised as described previously (data not shown) ([@B14]).

Gel filtration and N-terminal sequencing
----------------------------------------

N-terminal sequencing of LlaGI was carried out in-house at the Proteomics Facility. Analytical gel filtration was carried out using a 24 ml Superose 6 column (GE Healthcare). The column was pre-equilibrated at 0.4 ml/min with TMD buffer \[50 mM Tris--HCl (pH 8.0), 10 mM MgCl~2~, 1 mM DTT\] supplemented with 15 mM NaCl. A 100 µl loop was filled with protein sample in storage buffer \[30 mM Tris--Cl (pH 8.0), 0.6 mM EDTA, 240 mM NaCl, 0.6 mM DTT, 50% (v/v) glycerol\]. LlaGI was eluted with TMD plus 15 mM NaCl at 0.4 ml/min and monitored by measuring the absorbance at 280 nm. The Superose column was calibrated using thyroglobulin (669 kDa), apoferritin (443 kDa), β-amylase (200 kDa), alcohol dehydrogenase (150 kDa), BSA (66 kDa) and carbonic anhydrase (29 kDa). Blue dextran was used to calculate the void volume.

DNA cleavage assays
-------------------

Cleavage assays contained 4 nM DNA (supercoiled or linear), 4 mM ATP (or other nucleotide where indicated) and LlaGI (at the concentrations indicated) in TMD buffer. Where included, *S*-adenosyl methionine (AdoMet) was at 100 µM. Reactions were started by adding LlaGI to a mix of ATP, DNA and AdoMet (where present) in TMD buffer and incubated at 20°C for the times indicated. Other Type II RM endonucleases were added at concentrations recommended by the suppliers. Reactions were stopped with 0.5 volumes of 3× STEB \[0.1 M Tris (pH 7.5), 0.2 M EDTA, 40% (w/v) sucrose, 0.4 mg/ml bromophenol blue\]. Samples were analysed by agarose gel electrophoresis and, the percentage of ^3^H-labelled DNA in each band per lane was ascertained by scintillation counting ([@B13]), where required.

DNA methylation assays
----------------------

### Competition assays using EcoAI and EcoR124I

As indicated, 4 nM pHH-7 was methylated with 200 nM LlaGI~DA078~ ([@B11]), 40 nM M.EcoAI ([@B14]) or 100 nM M.EcoR124I ([@B14]) in TMD buffer supplemented with 4 mM ATP and 100 µM AdoMet. For methylation by M.EcoAI, the TMD buffer was supplemented with 50 mM NaCl. The reactions were incubated for 4 h on ice, at 20°C, at 25°C or at 37°C for untreated, LlaGI~DA078~, M.EcoAI or M.EcoR124I, respectively. Additional AdoMet was added after 1, 2 and 3 h and additional enzyme, where required, was added after 2 h. To each sample 0.1 volumes of 0.5 M EDTA was added and the DNA purified in three steps: (i) phenol/chloroform extraction and ethanol precipitation; (ii) by Qiagen PCR kit; and (iii) phenol/chloroform extraction and ethanol precipitation. The untreated and methylated DNA were then mixed with 4 mM ATP and 100 µM AdoMet in TMD buffer (supplemented with 50 mM NaCl for the EcoAI reactions), in the presence or absence of: 200 nM LlaGI; 400 nM M.EcoAI and 600 nM R.EcoAI; or, 40 nM M.EcoR124I and 300 nM R.EcoR124I. The reactions were incubated for 10 min on ice, at 20°C, at 25°C or at 37°C for no enzyme, LlaGI, EcoAI and EcoR124I, respectively. The reactions were stopped by the addition of 0.5 volumes of 3 x STEB containing 1 mg/ml Proteinase K and heated to 67°C for 20 min. The DNA substrates and products were separated by agarose gel electrophoresis.

### Relative methylation of the eight LlaGI recognition sequences

As indicated, 4 nM DNA (pZero, pOne, pHH-1, -2, -3, -6, -8, -9, -13, -14) and 200 nM LlaGI~DA078~ were incubated for 1 h at 37°C in NEBuffer 4 supplemented with 4 mM ATP and 100 µM \[^3^H-methyl\] AdoMet. AlwNI (0.5 U/μl) and NdeI (1 U/μl) were added to each tube and incubated further at 37°C for 1 h. The reactions were stopped by the addition of 0.1 volume 6 x STEB \[0.2 M Tris (pH 7.5), 0.4 M EDTA, 80% (w/v) sucrose, 0.8 mg/ml bromophenol blue\] and the DNA fragments separated by agarose gel electrophoresis. Fragment 1 containing Site α and Fragment 2 containing Site β were quantified by scintillation counting. Gel background counts were subtracted from all samples. The counts (dpm) from pZero fragment 1 (i.e. background) were subtracted from the counts of all other fragment 1 bands, and the counts from pZero Fragment 2 (i.e. background) were subtracted from the counts of all other Fragment 2 bands. The counts from each Fragment were then divided by the counts from pOne Fragment 1. The log~2~ of the resulting values were then calculated to give a linear scale (see legend to [Figure 7](#F7){ref-type="fig"}). Figure 4.DNA site requirements for cleavage by LlaGI. (**A** and **B**) Plasmid substrates with no sites, one-site or two indirectly-repeated sites were incubated with either saturating BamHI (B) or LlaGI (L) for 1 h. Substrates and products were separated by agarose gel electrophoresis as indicated. (**C** and **D**) Plasmid substrates with two directly-repeated sites (pHT-12) or two indirectly-repeated sites (pHH-12) were cleaved with either AlwNI (A) or NdeI (N) to produce the linear DNA indicated. Sequences of the LlaGI sites are in [Figure 3](#F3){ref-type="fig"}. The parental plasmids and linear DNA were then incubated with saturating LlaGI for 1 h. Substrates and products were separated by agarose gel electrophoresis as indicated. See main text for full details. Under these assay conditions, an additional slowly-migrating band was observed which we assign to a LlaGI-DNA bandshift. Gels labelled as in [Figure 3](#F3){ref-type="fig"}. Figure 5.Nucleotide dependence of DNA cleavage by LlaGI. Error bars represent standard errors from at least two repeat experiments. pHH-3 was incubated with excess LlaGI for 10 min in the absence or presence of 4 mM nucleotide, as indicated. Reaction products were separated by agarose gel electrophoresis and the extent of DNA cleavage quantified ('Materials and Methods' section). Figure 6.Stoichiometry and rate of DNA cleavage by LlaGI. Points are the mean of at least two repeat experiments. Note that where the FLL product becomes smeared due to end-processing, this can cause an overestimation of the CC band which overlaps with the smear. Similarly, smearing of the OC intermediate in part C causes the CC and FLL bands to be overestimated. This smearing most likely results from processing of the nicked DNA to form ssDNA gaps of different lengths (e.g. by exonucleolytic digestion from the nick). (**A**) pHH-3 ([Figure 3](#F3){ref-type="fig"}) was incubated with LlaGI at the concentrations indicated for 1 hr. (**B**) As (A) except in the presence of 100 µM AdoMet. (**C**) pHT-12 ([Figure 3](#F3){ref-type="fig"}) was incubated with LlaGI at the concentrations indicated for 1 h. (**D**) Time course of cleavage of pHH-3 with a saturating concentration of LlaGI (200 nM). (**E**) as (D) except in the presence of 100 µM AdoMet. (**F**) Time course of cleavage of pHT-12 with a saturating concentration of LlaGI (200 nM). Gels labelled as in [Figure 3](#F3){ref-type="fig"}. Figure 7.Methylation specificity of LlaGI. (**A**) Plasmid pHH-7 ([Figure 3](#F3){ref-type="fig"}) showing the overlapping EcoAI (blue), LlaGI (bold and yellow) and EcoR124I (red) sequences at Site β. Adenine residues methylated by EcoAI and EcoR124I are indicated by blue and red circles, respectively ([@B2]). (**B**) pHH-7 was treated with LlaGI~DA078~ (L), M.EcoAI (A) or M.EcoR124I (R), as indicated, in the presence of AdoMet. These DNA substrates were then treated with LlaGI (L), EcoAI (A) or EcoR124I (R), as indicated, in the presence of ATP and AdoMet. The DNA was then separated by agarose gel electrophoresis. See 'Materials and Methods' section and main text for full details. Note, cleavage by all three enzymes produces linear DNA that is further processed to generate a DNA smear. (**C**) pZero, pOne and pHH−1, −2, −3, −6, −8, −9, −13 and −14 ([Figure 3](#F3){ref-type="fig"}) were incubated with LlaGI~DA078~ and \[^3^H-methyl\] AdoMet for 1 h. The extent of ^3^H-labelling of each site was then assessed by scintillation counting ('Materials and Methods' section). For each plasmid, the labelling at each site was corrected for the gel background and the background from the corresponding fragments of pZero. Values were then normalised relative to Site α of pOne. These values are presented as a linear scale where positive values indicate increased labelling relative to Site α and negative values indicate reduced labelling relative to Site α. In pOne the region of Site β is random DNA and therefore acts as a non-specific control. The value of this should tend towards an infinitely small negative value. The observed value of ∼−6 therefore suggests a small background labelling of non-specific sites when a specific site is present on the DNA (i.e. the background labelling is higher than on pZero). In each plasmid the sequence at Site α is the same. Therefore, the values should all be zero, as in plasmid pOne. Given that the values for Sites α and β were very similar on each DNA, small variations between plasmids most likely represent different efficiencies of methylation that arise from variations in DNA preparation quality. Error bars represent the standard error from three repeat experiments.

RESULTS
=======

Site specificity of DNA cleavage by LlaGI
-----------------------------------------

The earlier study of LlaGI identified a region of pEW104 encompassed by the SacI and NsiI restriction sites as sufficient for *in vivo* RM activity ([@B1]). This region contains three genes: *repB*, *orfX* and *llagiRM* that appear to be co-transcribed from a single promoter ([Figure 1](#F1){ref-type="fig"}A). Whilst a similar gene arrangement is seen in some enzymes that are closely related to LlaGI (e.g. LlaBIII), it is not observed in other cases (e.g. RM.GthNGORF2804P) ([@B2]). Genes within a single operon may participate in a common metabolic pathway, but this is not always the case: co-transcribed proteins often simply perform broadly similar general functions, and may even have completely unrelated functions ([@B15],[@B16]). *repB* produces a protein associated with plasmid replication ([@B17]). *orfX* is often found associated with *repB* and a similar ORF has been identified in many lactococcal theta-replicating plasmids ([@B18; @B19; @B20; @B21]). The precise function of the *orfX* product remains mostly unknown: in some plasmids it may participate in copy number, stability, or both ([@B19],[@B21],[@B22]); however, it has been shown to be dispensable for plasmid replication in other cases and is sometimes completely absent ([@B23]). To determine whether the product of the *llagiRM* gene alone was sufficient for site-specific DNA recognition, methylation and cleavage, and whether orfX participated in these processes, we produced recombinant clones of native *llagiRM* and His-tagged *orfX* ('Materials and Methods' section).

Native LlaGI was over-expressed and purified to \>94% homogeneity using a three column method ([Figure 2](#F2){ref-type="fig"}A; 'Materials and Methods' section). (Induction of LlaGI expression was carried out at 27°C to optimise enzyme yield---data not shown). Analytical gel filtration under reaction buffer conditions (see below, 'Materials and Methods' section) resulted in a single peak, suggesting a single species. Using molecular weight standards to calibrate the column, we calculated an apparent MW for LlaGI of 187 kDa, similar to the predicted MW of 179 kDa and consistent with a monomeric species. N-terminal sequencing of the purified LlaGI indicated two protein populations; full-length protein and a nine amino acid N-terminal truncation (data not shown). These two species could not be resolved by gel filtration.

His-tagged OrfX was purified to \>80% homogeneity (data not shown; 'Materials and Methods' section). We tested if the DNA cleavage pattern of LlaGI was altered by the inclusion of the *orfx* gene product. No change in DNA cleavage specificity was observed (data not shown) and site-specific DNA cleavage, methylation and loop-translocation were obtained using LlaGI in isolation \[see below and refs ([@B10],[@B11])\]. We therefore find no evidence that the close association of *llagiRM*-related genes to *repB*- and/or *orxX*-like genes reflects the participation of *repB* and the *orfX* gene products in the LlaGI RM system. However, the close linkage may still be important during plasmid replication so that maintenance methylation and replication are temporally linked.

To ascertain the recognition sequence of LlaGI we used an *in vitro* approach similar to that used previously to analyse the Type III enzyme PstII ([@B24]). A library of arbitrary DNA plasmids (data available from M.D.S. on request) were screened for susceptibility to cleavage by a \>20-fold molar excess of LlaGI in the presence of ATP (predicted to be a necessary co-factor because of the presence of the helicase domain) ('Materials and Methods' section). Cleavage activity was largely independent of the buffer components and AdoMet was not obligatory, although some stimulation of the cleavage reaction was observed (see below and [Figure 6](#F6){ref-type="fig"}). We did not note any differences in the cleavage patterns when we tested DNA purified from a *dam^-^/dcm*^-^ strain (GM2929---ref. [@B25]) (data not shown). Secondary cleavage with suitably located Type II restriction enzymes revealed that cleavage by LlaGI resulted in a smear of DNA fragments of variable lengths reminiscent of the cleavage patterns of Type I RM enzymes (see below) ([@B26; @B27; @B28]). We therefore, assumed that LlaGI used a similar mechanism; i.e. DNA cleavage occurs as the result of communication and collision between two enzymes originating from two recognition sites located on either side of the cleavage loci. Using primer walking, a library of PCR substrates was then generated in which one end of the DNA was iteratively shortened. These DNA substrates were tested for dsDNA cleavage. When DNA cleavage activity was lost, it was assumed that the recognition site was no longer copied by the PCR and that the LlaGI site resided in the region of DNA up to the previous primer in the series. (As part of this process, we found that LlaGI would not cut a DNA if its site was within 30 bp of a free DNA end; data not shown). Several DNA regions that were indentified as containing a possible site were analysed to identify common sequences of 6 ± 1 bp in length. To make sense of our results we also had to make the assumption that dsDNA cleavage only occurred when the sites were found in an indirectly-repeated orientation (the directionality of the site is defined in [Figure 1](#F1){ref-type="fig"}C). This process identified the sequence 5′-CTnGAyG-3′, giving a total of eight possible LlaGI sequences.

To confirm the recognition sequence, we created a library of two-site DNA substrates using as the parental plasmid pOne, which contained only one putative sequence, named site α ([Figure 3](#F3){ref-type="fig"}A, 'Materials and Methods' section). The 14 DNA sequences tested were designed to represent the eight variations of the putative LlaGI site (i.e. all combinations of the degenerate positions) and to also test variations in adjacent non-specific sequence ([Figure 3](#F3){ref-type="fig"}B). dsDNA cleavage (as judged by the appearance of linear DNA) was only observed when the pair of LlaGI sites were in an indirectly-repeated orientation ([Figures 3](#F3){ref-type="fig"}A and B). All eight versions of the LlaGI site resulted in dsDNA cleavage, with no measurable preference for any other bases in the flanking DNA sequences. Plasmids are named hereafter with a numeric suffix ([@B1; @B2; @B3; @B4; @B5; @B6; @B7; @B8; @B9; @B10; @B11; @B12; @B13; @B14]) to indicate the 'top strand' sequence of Site β (and adjacent DNA), Site α being constant.

The recognition site requirements for DNA cleavage by LlaGI are summarised in [Figure 4. Cleavage](#F4){ref-type="fig"} of circular plasmid DNA was not observed in the absence of a recognition site (pZero, [Figure 4](#F4){ref-type="fig"}A and B). In the presence of a single site (pOne), efficient DNA nicking was observed without the formation of linear DNA. In the presence of two indirectly-repeated sites (pHH-3), dsDNA cleavage resulted in the formation of linear DNA (also for pHH-12 in [Figure 4](#F4){ref-type="fig"}C and D). If the two sites were directly repeated (pHT-12), only DNA nicking was observed ([Figure 4](#F4){ref-type="fig"}D), similar to the result on pOne. On the pHH-3 and pHH-12 substrates, cleavage could result from interactions between the sites via the head-to-head and/or tail-to-tail DNA arcs. We therefore also generated a series of linear DNA substrates in which the pair of LlaGI sites were oriented either head-to-tail (HT), head-to-head (HH) or tail-to-tail (TT), as defined by the site orientation in [Figure 1](#F1){ref-type="fig"}C ([Figure 4](#F4){ref-type="fig"}C). The plasmid DNA was cut first by a Type II RM enzymes ('1st enzyme', as indicated) and then treated with LlaGI ('2nd enzyme', as indicated) ([Figure 4](#F4){ref-type="fig"}D). dsDNA cleavage by LlaGI was only observed when the sites were in a head-to-head orientation. Note that we cannot measure DNA nicking of the linear DNA in this assay. The smear of DNA products observed with the HH substrate had a size distribution consistent with cleavage within the region between the sites. A similar distribution of cleavage loci exclusively in the HH DNA arc was also observed following cleavage of plasmid DNA (data not shown).

Nucleotide-dependence of the DNA cleavage activity of LlaGI
-----------------------------------------------------------

Using the two-site plasmid pHH-3, we tested the nucleotide-dependence of the cleavage reaction ([Figure 5](#F5){ref-type="fig"}). LlaGI was incubated with ^3^H-labelled pHH-3 for 10 min under the conditions indicated, and the relative levels of substrate (CC), intermediate (OC) and full length linear product (FLL) quantified ('Materials and Methods' section). Efficient dsDNA cleavage was only observed in the presence of either ATP or dATP. In the complete absence of nucleotide, incomplete DNA nicking was observed. This nicking activity was stimulated moderately by ATPγS and CTP, but still at a reduced level compared to the activity with ATP or dATP. All subsequent assays here and in the accompanying manuscripts ([@B10],[@B11]) were carried out with ATP.

Rate and stoichiometry of DNA cleavage by LlaGI
-----------------------------------------------

The reactions above used an excess of LlaGI over DNA and were incubated until no further DNA cleavage occurred (reaction time of ≥10 min). To assess further the DNA cleavage mechanism of LlaGI, we measured the extent of DNA cleavage at the reaction 'end point' as a function of the LlaGI:DNA molecular ratio and measured the rate of one- and two-strand DNA cleavage at a saturating concentration of LlaGI. The effect of the MTase cofactor AdoMet was assessed in each case.

### Cleavage stoichiometry

Titration of LlaGI with ^3^H-labelled pHH-3 in the absence of AdoMet is shown in [Figure 6](#F6){ref-type="fig"}A. Complete DNA cleavage (as judged by the appearance of \>90% FLL DNA) was only obtained with \>10 LlaGI molecules per DNA molecule (five monomers per site). Below this concentration, nicked DNA accumulated. At the highest enzyme concentrations examined the linear DNA was further processed to produce a smear. The distribution of the DNA products indicates an exonuclease activity. A similar reaction profile was observed in the presence of AdoMet except that complete DNA cleavage was obtained with \>5 LlaGI monomers per DNA molecule (two to three monomers per site) ([Figure 6](#F6){ref-type="fig"}B). In addition to its role as a methyl donor, AdoMet has been widely demonstrated to have a second role for methyltransferases as an allosteric activator of DNA binding ([@B29],[@B30]). The data in [Figure 6](#F6){ref-type="fig"}B is consistent with such a role in LlaGI. The exonucleolytic processing of the linear product DNA also occurred at lower protein concentrations with AdoMet (note, this produces an artificial increase in the CC substrate---see legend to [Figure 6](#F6){ref-type="fig"}).

A requirement for multiple LlaGI molecules per site can be explained by a number of different models which are not mutually exclusive: (i) dsDNA cleavage requires the interaction of multiple LlaGI molecules. For example, a requirement for a dimer of LlaGI at each recognition site would be consistent with the data in [Figure 6](#F6){ref-type="fig"}B; (ii) The DNA-binding affinity is relatively low under our reaction conditions; or (iii) the proportion of inactive LlaGI in our preparations is relatively high (i.e. a low specific activity).

Titration of LlaGI with ^3^H-labelled pHT-12 in the absence of AdoMet is shown in [Figure 6](#F6){ref-type="fig"}C. Full DNA nicking activity (\>80% OC produced) was observed with \>2 LlaGI molecules per site. Full nicking activity was also seen on pHH-3 at the same molar ratio ([Figure 6](#F6){ref-type="fig"}A). This suggests that the nicking of both plasmids requires the same amount of LlaGI molecules per site but that cleavage of the second strand of pHH-3 to generate a dsDNA break requires additional enzyme molecules. At the higher enzyme concentrations, the nicked DNA band becomes smeared, producing an apparent increase in the CC concentration because of overlapping DNA mobilities.

### Cleavage rate

A time course of pHH-3 cleavage in the presence of excess LlaGI (25 per site) and in the absence of AdoMet is shown in [Figure 6](#F6){ref-type="fig"}D. The reaction profile shows that nicked DNA is a significant intermediate in the reaction, reaching a maximum of \>50%. This is higher than the ∼33% expected for a reaction in which each strand cleavage rate is identical. This could arise because, either the rate of the first strand cleavage is faster than the second or, the long-range communication between the LlaGI sites collapses before both strand cleavages can occur. We cannot distinguish between these alternatives given our current data. In the presence of AdoMet, the rate and profile of DNA cleavage were very similar ([Figure 6](#F6){ref-type="fig"}E). Whilst AdoMet can enhance protein--DNA interactions, once DNA binding is saturated, AdoMet does not alter the reaction pathway.

The rate of DNA nicking of pHT-12 in the presence of excess LlaGI and in the absence of AdoMet is shown in [Figure 6](#F6){ref-type="fig"}F. The nicking rate was ∼3-fold slower than that observed on pHH-3 under the same conditions. The difference in these values is consistent with a different cleavage pathway for sites in direct or indirect repeat.

Site specificity of DNA methylation by LlaGI
--------------------------------------------

The amino acid sequence of the MTase domain of LlaGI has an arrangement of catalytic motifs consistent with the adenine-specific γ sub-family ([@B1],[@B31]). The eight LlaGI recognition sequences ([Figures 1](#F1){ref-type="fig"}C and [3](#F3){ref-type="fig"}B) contain two invariant adenine residues, one on each strand, which are potential targets for methylation. In some sites adenine residues also occur at the degenerate positions and it is possible that these are also targets for modification. We first tested the invariant adenine residues. One of the two-site indirectly repeated plasmids described earlier (pHH-7) had been designed such that site β overlaps with the recognition sequences for the Type I RM enzymes EcoR124I and EcoAI ([Figure 7](#F7){ref-type="fig"}A). The methylation specificity of one half site of EcoR124I or EcoAI corresponds to each putative target adenine residue in the LlaGI site. pHH-7 was first methylated using full-length LlaGI~DA078~ \[an endonuclease mutant that cannot cleave DNA but which has wild type translocation properties ([@B11])\], M.EcoAI or M.EcoR124I ('Materials and Methods' section). Each methylated DNA was then incubated separately with each endonuclease and the extent of DNA cleavage ascertained ([Figure 7](#F7){ref-type="fig"}B). In each case endonuclease activity was almost completely blocked by the cognate MTase, as expected. (The small amount of cleavage observed with EcoR124I represents the inefficient *de novo* methylation of the Type I MTases.) However, whilst methylation by EcoR124I had no effect on LlaGI (and vice versa), the methylation activities of LlaGI and EcoAI blocked both endonucleases. These results are consistent with methylation by LlaGI of the adenine residue on the bottom strand at the second base pair ([Figure 1](#F1){ref-type="fig"}C) but not at the adenine residue on the top strand at the fifth base pair. Attempts to confirm this result using oligoduplexes containing a synthetic N6-methyl deoxyadenosine residue were unsuccessful (data not shown). This may be the result of the large amount of adjacent DNA required for LlaGI activity/binding (noted above).

The data in [Figure 7](#F7){ref-type="fig"}B deals exclusively with the constant adenine residues found in all the possible LlaGI recognitions sequences ([Figure 3](#F3){ref-type="fig"}B). For two of the eight sites (CTCGACG and CTGGACG), there are no other adenine residues and the sites can only ever be hemi-methylated. However, for the other six versions of the site, adenine residues can also be found at one or both of the degenerate positions. It is possible that these residues may also be targets for methylation by LlaGI. Using the library of two-site DNA generated to test the DNA cleavage activity ([Figure 3](#F3){ref-type="fig"}, 'Materials and Methods' section), we monitored the extent of DNA methylation of each of the eight sites relative to a constant site (Site α, [Figure 3](#F3){ref-type="fig"}) using \[^3^H-methyl\] AdoMet ([Figure 7](#F7){ref-type="fig"}C, 'Materials and Methods' section). All of the eight sites were methylated to the same extent. The sequence at site α contains one degenerate adenine ([Figure 3](#F3){ref-type="fig"}B). The other sites contain either 0, 1 or 2 degenerate adenines. Therefore, if any of the degenerate residues were targets we would have expected a two-fold increase or decrease to be observed on some substrates. As this was not observed, these data show that all eight LlaGI sites were methylated at the same single adenine, i.e. LlaGI only hemi-methylates DNA regardless of the recognition sequence. Note, the data in [Figure 7](#F7){ref-type="fig"}B also shows that hemi-methylation of only one of the two sites (by pre-treatment with M.EcoAI) is sufficient to prevent dsDNA cleavage (but not the Site α-dependent nicking activity).

DISCUSSION
==========

Our characterisation of the DNA cleavage and methylation activities of the single polypeptide RM enzyme LlaGI shows that whilst this enzyme shares some features with the classical Type I RM enzymes, it also has activities and features in common with Type II and III RM enzymes. The 7-nt DNA recognition sequence of LlaGI ([Figure 1](#F1){ref-type="fig"}C) is distinct from the bipartite sequences of the classical Type I enzymes \[e.g. GAANNNNNNRTCG for EcoR124I, where R is any purine, ([@B2])\]. This is perhaps unsurprising, given that bioinformatics analysis does not indicate the presence of an HsdS (or half HsdS) domain in LlaGI. Where some Type II enzymes contain HsdS-like domains they also recognise bipartite sequences ([@B2]). The LlaGI recognition sequence is also distinct from the short asymmetric sequences of the Type III enzymes which are 6 bp or less in length and do not contain degenerate base pairs \[e.g. CTGATG for PstII ([@B2],[@B24])\]. However, similar seven base pair semi-redundant sequences have been identified for some ATP-independent, single polypeptide Type IIS RM enzymes \[e.g. CGRGGAC for RpaB5I and CAAGNAC for DraRI, ([@B2])\]. Outside of highly conserved MTase amino acid motifs, there does not appear to be any sequence relationship between LlaGI and these enzymes (data not shown).LlaGI only hemi-methylates its recognition sequences ([Figure 7](#F7){ref-type="fig"}) which could cause a problem following semi-conservative replication as unmethylated sites will occur on the daughter DNA \[[Figure 8](#F8){ref-type="fig"} ([@B32],[@B33])\]. Hemi-methylation is also a feature of all Type III enzymes studied to date whereas in contrast, the Type I enzymes methylate both DNA strands ([@B2]). Where ATP-independent Type II enzymes recognise an asymmetric sequence, methylation of both DNA strands is achieved by using either two separate, independent MTases (e.g. HphI), or a single polypeptide that is the fusion of two independent MTases (e.g. FokI) ([@B2]). More recently however, the single polypeptide Type IIS RM enzyme MmeI and related enzymes have been identified that can only hemi-methylate their recognition sequences (e.g. TCCR[A]{.ul}C for MmeI, where the adenine underlined is modified whilst the adenine complementary to the first T residue is not) ([@B2],[@B9],[@B34]). The consequences of hemi-methylation are considered in more detail below.Whilst a DNA nicking activity is observed in the presence of a single LlaGI site, full dsDNA cleavage only occurs when two LlaGI sites are present in a head-to-head orientation ([Figures 3](#F3){ref-type="fig"} and [4](#F4){ref-type="fig"}). This is different to the classical Type I enzymes where dsDNA cleavage is independent of the relative site orientation ([@B27]), and only requires a single site on circular DNA ([@B35]). Instead the activity is more similar to the Type III enzymes ([@B5],[@B24],[@B32],[@B33]). It has been suggested that the requirement for site orientation specificity by Type III enzymes is the direct consequence of the incomplete methylation of the recognition site ([@B32]). By requiring the presence of two indirectly repeated sites, at least one of the pair remains hemi-methylated following replication ([Figure 8](#F8){ref-type="fig"}). We directly demonstrate here that methylation of one LlaGI site of a pair is sufficient for protection from dsDNA cleavage ([Figure 7](#F7){ref-type="fig"}B). We suggest that the requirement for a pair of directional sites for DNA cleavage by LlaGI evolved to compensate for the incomplete methylation of the site that would otherwise result in lethal dsDNA breaks. However, the single unmethlyated site still results in DNA nicking. Whilst not as lethal as a dsDNA break, nicks could result in fork arrest if they are not repaired before the next round of replication ([@B36]). Figure 8.The consequences of recognition site hemi-methylation following replication, adapted from the model of Meisel *et al*.([@B32],[@B33]). The LlaGI site is indicated as an arrowhead ([Figure 1](#F1){ref-type="fig"}C), the methylated site by a circle and the newly synthesised DNA in red. (**A**) Where two sites are in head-to-head repeat, one site of the pair is methylated in each of the daughter DNAs and both are protected from dsDNA cleavage ([Figure 7](#F7){ref-type="fig"}). (**B**) With two sites in head-to-tail repeat, both sites in one daughter DNA are completely unmethylated. However, this arrangement of sites does not result in a dsDNA break ([Figures 3](#F3){ref-type="fig"} ands [4](#F4){ref-type="fig"}). DNA nicking that result from the unmethylated sites is likely to be repaired before the replication fork next passes.Although LlaGI and the Type III enzymes share the same requirement for ATP hydrolysis and a pair of indirectly-repeated recognition sites, LlaGI cleaves at random loci in the DNA between a pair of head-to-head sites whilst the Type III enzymes cleave ∼25--27 bp downstream of one or other site ([@B2]). The random cleavage profile of LlaGI is very similar to the distributive cleavage pattern of the classical Type I enzymes ([@B26],[@B27]), which results from the convergent collision of enzymes that are translocating from the sites ([@B28]). In the accompanying manuscript we demonstrate that LlaGI has ATPase and loop translocation activities similar to that of the classical Type I RM enzymes and quite distinct to the Type III RM enzymes ([@B10],[@B11]). However, whilst the classical Type I enzymes translocate bidirectionally from their sites ([@B37]), LlaGI catalyses unidirectional translocation. A model for how translocation leads to DNA cleavage is illustrated in the accompanying paper ([@B10]).The DNA cleavage profiles shows that nicked DNA is a major intermediate during dsDNA cleavage ([Figure 6](#F6){ref-type="fig"}). A similar accumulation of nicked DNA is seen for some classical Type I enzymes, except that the maximum percentage observed is usually \<33% ([@B35], Frank Peske unpublished observations). Type III RM enzymes accumulate virtually no nicked DNA intermediate ([@B30]), which is most likely related to the rate-limiting ATPase activity that precedes DNA cleavage ([@B33]). Since we show in the accompanying manuscript that LlaGI communicates between its sites using a mechanism similar to that of the classical Type I enzymes ([@B10]), the differences in the reaction profiles most likely reflects differences in the DNA cleavage steps rather than communication steps. In the third accompanying manuscript ([@B11]) we show that LlaGI uses an Mrr nuclease domain distinct to the RecB-family nuclease domain of the classical Type I RM enzymes. Although both are part of the PD(D/E)xK superfamily of nucleases ([@B3]), it is possible that dsDNA cleavage proceeds by different mechanisms.

From the data in this paper and the accompanying manuscripts ([@B10],[@B11]), we can compare the domain structure and enzyme activities of LlaGI to that of Type I, II and III RM enzymes ([Table 2](#T2){ref-type="table"}). The Type II RM enzymes represent a diverse class with varied domain/subunit architectures and a broad repertoire of enzyme activities. Here we have chosen to only compare a sub-grouping that are most similar to LlaGI, the Type IIL enzymes, as exemplified by MmeI ([@B34]). Whilst some features of LlaGI activity are clearly Type I-like (the presence of similar helicase and MTase domains, an extensive ATPase activity, dsDNA loop translocation, distributive non-specific DNA cleavage loci), others are Type III-like (a requirement for two sites with a particular orientation, single-strand methylation) or Type IIL-like (short degenerate recognition sequence, single-strand methylation, single polypeptide multi-domain arrangement). The classification of Type I and III enzymes was historically on the basis of gene arrangement (Type I enzymes comprising HsdS, HsdM and HsdR subunits, Type III enzymes comprising Mod and Res subunits). Subsequent biochemical analysis has shown that both Types have enzyme behaviour that is largely family-specific and distinct. We suggest that given the presence of a helicase domain that couples extensive ATP hydrolysis to loop translocation ([@B10]), LlaGI is most closely related to the Type I enzymes and should be classified as such. However, to distinguish the single polypeptide enzymes from the classical multi-subunit enzymes, we suggest the nomenclature Type I SP (for single polypeptide). This avoids confusion with the single letter suffices that have already been assigned to sub-families of Type I enzymes from enterobacteria (on the basis of gene complementation and antibody cross-reactivity) and to the Type II enzymes (on the basis of gene and enzyme properties) ([@B38]). Our classification redefines the Type I enzymes in more general terms as dsDNA loop translocases that cleave DNA at random sites distant from their recognition sequences. The classification of the Type III enzymes remains open to discussion, as DNA looping, DNA loop translocation, DNA translocation and bi-directional DNA sliding models have all been proposed and a consistent mechanism has yet to emerge. Table 2.Genetic and biochemical classification of LlaGIType IType IIIType IILType ISPe.g. EcoR124Ie.g. EcoPIe.g. MmeIe.g. LlaGIGenes/protein    GenesHsdR, hsdM, hsdSRes, modRMRM    Nuclease ComplexR~2~M~2~S~1~Res~2~Mod~2~n.d.RM~1~ (RM~2~ for cleavage?)    Recognition sequenceAsymmetric, bipartite GAAnnnnnnRTCGShort, asymmetric AGACCShort, asymmetric, degenerate TCCrACShort, asymmetric, degenerate CTnGAyGDNA methylation    MethylationBoth strandsOne strandOne strandOne strandDNA cleavage    CofactorsATP, Mg^2+^, AdoMetATP, Mg^2+^Mg^2+^ATP, Mg^2+^    Multiple sites required?Yes, Linear DNANo, circular DNAYes (+AdoMet) No (-AdoMet)^a^YesYes (dsDNA break) No (nicking)    Sites required *in cis*?YesYesNoYes    Communication mode1D1D3D1D    Preference for site directionality?NoneIndirect repeat^b^NoneIndirect Repeat (head-to-head only)    Cleavage loci?Non-specific randomNon-specificNon-specificNon-specific randomDistant and proximalFixed proximalFixed proximalDistant and proximalHelicase motor activity*No helicase domain*    DNA Loop translocation requiredYesNoYes    DNA SupercoilingYesNoYes    DirectionalityBidirectional (two unidirectional motors per complex)Bidirectional^b^Unidirectional    Translocation rate463 bp/s (20°C)n.d.173 ATP/s (20°C)    ATPase rate503 ATP/s/motor(20°C)∼0.2 ATP/s/per complex (20°C)250 ATP/s (20°C)    ATP per bp1--1.5«11.5--2    Step size1--2n.d.n.d.    Average distance moved per event∼5000 bpn.d.n.d.    Motor polarity3′--5′n.d.n.d.    Triplex displacementYesNoYes[^3][^4][^5]
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[^1]: Present address: Jytte Josephsen, Øresund Food Network, Nørre Voldgade 16, DK 1358, Copenhagen K, Denmark.

[^2]: Two distinct subgroups were observed with distinct sequences at helicase Motif I (the Walker A box). Note that some of these sequences have N-terminal deletions and/or mutations that may result in an inactive nuclease.

[^3]: Data for EcoR124I was collated from refs ([@B14],[@B27],[@B35],[@B39; @B40; @B41]). Data for EcoPI was collated from refs ([@B30],[@B42; @B43; @B44; @B45]). Data for MmeI was collated from refs ([@B2],[@B9],[@B34]). Data for LlaGI was from this paper and refs. 1,10,11. n.d. is where data is not determined.

[^4]: ^a^Relaxed cleavage conditions with high enzyme:DNA ratios.

[^5]: ^b^Dogma states that Type III enzymes only cut sites in head-to-head repeat ([@B33]) but more recent analysis suggests that tail-to-tail repeats are cut equally well (Kara van Aelst, M.D.S. and Ralf Seidel, unpublished data).
